4.5 Article Proceedings Paper

Phosphoproteomic Analysis as an Approach for Understanding Molecular Mechanisms of cAMP-Dependent Actions

Journal

MOLECULAR PHARMACOLOGY
Volume 99, Issue 5, Pages 342-357

Publisher

AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/molpharm.120.000197

Keywords

-

Funding

  1. National Institutes of Health National Institute of General Medical Sciences [R01-GM083926]
  2. National Heart, Lung, and Blood Institute [R35-HL150754]
  3. National Institute of Diabetes and Digestive and Kidney Diseases [P30-DK017047]
  4. National Institute of General Medical Sciences [R01GM086858, R01-GM129090]
  5. National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01-AR065459]
  6. National Institute of Biomedical Imaging and Bioengineering [R21-EB018384]
  7. National Cancer Institute [R21-CA177402, K22-CA201229-01]

Ask authors/readers for more resources

Highly sensitive mass spectrometry-based phosphoproteomic analysis has been applied to study changes in protein kinase substrates related to cAMP. These analyses suggest that multiple phosphorylation sites may regulate cAMP-dependent pathways, contrary to previous assumptions of single or few rate-limiting steps being affected by phosphorylation. Additionally, the stoichiometry of phosphorylation may not always be a key factor in regulating function.
In recent years, highly sensitive mass spectrometry-based phosphoproteomic analysis is beginning to be applied to identification of protein kinase substrates altered downstream of increased cAMP. Such studies identify a very large number of phosphorylation sites regulated in response to increased cAMP. Therefore, we now are tasked with the challenge of determining how many of these altered phosphorylation sites are relevant to regulation of function in the cell. This minireview describes the use of phosphoproteomic analysis to monitor the effects of cyclic nucleotide phosphodiesterase (PDE) inhibitors on cAMP-dependent phosphorylation events. More specifically, it describes two examples of this approach carried out in the authors' laboratories using the selective PDE inhibitor approach. After a short discussion of several likely conclusions suggested by these analyses of cAMP function in steroid hormone-producing cells and also in T-cells, it expands into a discussion about some newer and more speculative interpretations of the data. These include the idea that multiple phosphorylation sites and not a single rate-limiting step likely regulate these and, by analogy, many other cAMP-dependent pathways. In addition, the idea that meaningful regulation requires a high stoichiometry of phosphorylation to be important is discussed and suggested to be untrue in many instances. These new interpretations have important implications for drug design, especially for targeting pathway agonists. SIGNIFICANCE STATEMENT Phosphoproteomic analyses identify thousands of altered phosphorylation sites upon drug treatment, providing many possible regulatory targets but also highlighting questions about which phosphosites are functionally important. These data imply that multistep processes are regulated by phosphorylation at not one but rather many sites. Most previous studies assumed a single step or very few rate-limiting steps were changed by phosphorylation. This concept should be changed. Previous interpretations also assumed substoichiometric phosphorylation was not of regulatory importance. This assumption also should be changed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available